ATXI
AVENUE THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.40
−6.07%Price chart
Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3
Key dataNov 3, 2026
Open$0.40
From 52W high−56.47%
Volume5000.00
Market cap$1.28M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 3, 2026
Open
$0.40
From 52W high
−56.47%
Volume
5000.00
Market cap
$1.28M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
47.4
MomentumView details →
1D Return
−6.07%
YTD Return
−40.92%
SummaryUpdated Jun 1, 2026
Avenue Therapeutics, Inc. (NASDAQ:ATXI) is a specialty pharmaceutical company founded in 2015 and headquartered in New York, New York. The company went public in June 2017 and focuses on developing and commercializing pharmaceutical products specifically designed for use in acute and intensive care hospital settings. Avenue Therapeutics operates as a clinical-stage biotechnology company with its primary asset being an intravenous formulation of Tramadol currently in Phase III clinical trials.
Similar companies
Latest newsMore news →
No recent news for ATXI.